{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:50:20Z","timestamp":1785790220304,"version":"3.56.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      To evaluate the long-term efficacy, safety, and survival outcomes of at least 4 treatment cycles of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTA-IBA therapy in patients with bone metastases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      This single-center retrospective cohort study enrolled patients with bone metastases who initiated therapy between November 2021 and May 2024 and completed \u22654 cycles of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTA-IBA. The primary endpoints were symptom improvement [Numerical Rating Scale (NRS) and Karnofsky Performance Status (KPS)], safety (Common Terminology Criteria for Adverse Events v5.0), and overall survival. Longitudinal efficacy changes were analyzed using linear mixed-effects models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fifty-six patients were included: 31 completed 4\u20135 cycles and 25 completed 6\u201310 cycles. Pharmacokinetic analysis (n=20) demonstrated a longer effective half-life in lesions than in the whole body, with progressively increasing target-to-nontarget uptake ratios over time. Treatment-related myelosuppression of any grade occurred in 8 patients (14.3%), renal toxicity in 4 (7.1%), and grade 3 thrombocytopenia in 1 (1.8%); no other grade 3\u20134 adverse events were observed. Increasing treatment cycles were not associated with increased hematological or renal toxicity. The best overall pain response rate (NRS reduction \u226550%) was 88.5%, and KPS improvement was observed in 79.6% of patients. Longitudinal analysis demonstrated cumulative therapeutic benefit, with continuous NRS reduction and KPS improvement across cycles. Disease progression during treatment independently predicted shorter survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      For patients with bone metastases who can tolerate multicycle therapy, long-term\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTA-IBA treatment yields cumulative symptom improvement with no significant increase in cumulative toxicity risk, supporting its use as a long-term therapeutic strategy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006570","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:00:19Z","timestamp":1780927219000},"page":"771-781","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Long-term Safety and Cumulative Efficacy of Multicycle 177Lu-DOTA-IBA Therapy in Bone Metastases: A Retrospective Cohort Study"],"prefix":"10.1097","volume":"51","author":[{"given":"Tingting","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2096-4907","authenticated-orcid":false,"given":"Ke","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4088-7649","authenticated-orcid":false,"given":"Yue","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranostics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"R1-20260803","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jbo.2017.01.001","article-title":"Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration","volume":"6","author":"Nooh","year":"2017","journal-title":"J Bone Oncol"},{"key":"R2-20260803","first-page":"771","article-title":"Analgesia and curative effect of pamidronate disodium combined with chemotherapy on elderly patients with advanced metastatic bone cancer","volume":"18","author":"Liu","year":"2019","journal-title":"Oncol Lett"},{"key":"R3-20260803","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1007\/s00259-008-0841-y","article-title":"EANM procedure guideline for treatment of refractory metastatic bone pain","volume":"35","author":"Bodei","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R4-20260803","first-page":"38S","article-title":"Bone-seeking radionuclides for therapy","volume":"46","author":"Lewington","year":"2005","journal-title":"J Nucl Med"},{"key":"R5-20260803","doi-asserted-by":"crossref","first-page":"159","DOI":"10.23736\/S1824-4785.19.03177-7","article-title":"Leveraging the power of non-radium radionuclide treatments in bone metastases","volume":"63","author":"Thapa","year":"2019","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R6-20260803","first-page":"4829","article-title":"An automated synthesis of 177Lu-EDTMP as an efficient bone-seeking therapeutic radiopharmaceutical","volume":"25","author":"Elboga","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R7-20260803","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1021\/acs.molpharmaceut.2c00978","article-title":"Lutetium177-labeled DOTA-ibandronate: a novel radiopharmaceutical for targeted treatment of bone metastases","volume":"20","author":"Wang","year":"2023","journal-title":"Mol Pharm"},{"key":"R8-20260803","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/RLU.0000000000004634","article-title":"Safety and efficacy of 68Ga- or 177Lu-labeled DOTA-IBA as a novel theranostic radiopharmaceutical for bone metastases: a phase 0\/I study","volume":"48","author":"Qiu","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R9-20260803","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/RLU.0000000000005573","article-title":"Efficacy and safety of 177Lu-DOTA-IBA in tumor bone metastasis treatment: a prospective clinical trial","volume":"50","author":"Xu","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R10-20260803","doi-asserted-by":"crossref","first-page":"8163","DOI":"10.3390\/ijms25158163","article-title":"Balancing the scales: the dual role of interleukins in bone metastatic microenvironments","volume":"25","author":"Dawalibi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R11-20260803","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO.2004.08.181","article-title":"Bone imaging in metastatic breast cancer","volume":"22","author":"Hamaoka","year":"2004","journal-title":"J Clin Oncol"},{"key":"R12-20260803","doi-asserted-by":"crossref","first-page":"1027792","DOI":"10.3389\/fonc.2022.1027792","article-title":"Preparation, biological characterization and preliminary human imaging studies of 68Ga-DOTA-IBA","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"R13-20260803","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/RLU.0000000000004757","article-title":"Biodistribution and internal dosimetry of 68Ga-DOTA-IBA PET imaging for patients with bone metastases","volume":"48","author":"Yang","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R14-20260803","first-page":"383","article-title":"177Lu-EDTMP for metastatic bone pain palliation: a systematic review and meta-analysis","volume":"36","author":"Askari","year":"2021","journal-title":"Cancer Biother Radiopharm"},{"key":"R15-20260803","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.2174\/0929867326666190201142814","article-title":"Targeted radionuclide therapy of painful bone metastases: past developments, current status, recent advances and future directions","volume":"27","author":"Dash","year":"2020","journal-title":"Curr Med Chem"},{"key":"R16-20260803","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s13139-017-0509-2","article-title":"Treatment of bone metastasis with bone-targeting radiopharmaceuticals","volume":"52","author":"Choi","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"R17-20260803","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.3390\/jcm9082622","article-title":"Targeted palliative radionuclide therapy for metastatic bone pain","volume":"9","author":"Manafi-Farid","year":"2020","journal-title":"J Clin Med"},{"key":"R18-20260803","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2967\/jnumed.121.263310","article-title":"223Ra induces transient functional bone marrow toxicity","volume":"63","author":"Parlani","year":"2022","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:01:43Z","timestamp":1785787303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006570","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"2026-01-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}